July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Sapna Patel: An important pathway in cancer signaling, including melanoma
Jul 8, 2024, 05:44

Sapna Patel: An important pathway in cancer signaling, including melanoma

The Video Journal of Oncology (VJOncology) shared on LinkedIn:

“New from ASCO2024: Phase I trial of SX-682, a CXCR1/2 inhibitor, in metastatic melanoma.

Sapna Patel, BA, MD, The University of Texas MD Anderson Cancer Center, remarks on a Phase I trial (NCT03161431) examining SX-682, a CXCR1/2 inhibitor, in combination with pembrolizumab in patients with metastatic melanoma resistant to anti-PD-1 therapy.

Patients received increasing doses of SX-682, with primary endpoints focusing on safety and tolerability, and secondary endpoints including objective response rate (ORR) and overall survival (OS).

The results indicated a tolerable safety profile and encouraging clinical activity, with a notably longer median OS in this cohort. Learn more.”

Sapna Patel,

“This is an important pathway in cancer signaling, including melanoma.

Targeting CXCR1/2 signaling is not new, but this *new* small molecule inhibitor managed to generate responses in PD-1 refractory disease, including those whose melanoma had previously responded to immune checkpoint blockade.”

Source: Video Journal of Oncology (VJOncology)/LinkedIn and Sapna Patel/LinkedIn